Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Mallinckrodt
AstraZeneca
Colorcon
Dow

Last Updated: February 7, 2023

Details for Patent: 8,388,941


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,388,941 protect, and when does it expire?

Patent 8,388,941 protects TRAVATAN Z and is included in one NDA.

This patent has sixteen patent family members in thirteen countries.

Summary for Patent: 8,388,941
Title:Self preserved aqueous pharmaceutical compositions
Abstract: The use of a borate/polyol and zinc system to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being `self-preserved`. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for aqueous ophthalmic compositions.
Inventor(s): Chowhan; Masood A. (Arlington, TX), Keith; David J. (Washington, MO)
Assignee: Alcon Research, Ltd. (Fort Worth, TX)
Application Number:12/441,995
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,388,941
Patent Claim Types:
see list of patent claims
Composition; Use;

Drugs Protected by US Patent 8,388,941

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis TRAVATAN Z travoprost SOLUTION/DROPS;OPHTHALMIC 021994-001 Sep 21, 2006 AT RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,388,941

PCT Information
PCT FiledSeptember 20, 2007PCT Application Number:PCT/US2007/079094
PCT Publication Date:April 10, 2008PCT Publication Number: WO2008/042619

International Family Members for US Patent 8,388,941

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007304996 See Plans and Pricing
Brazil PI0717093 See Plans and Pricing
Canada 2663817 See Plans and Pricing
China 101522171 See Plans and Pricing
European Patent Office 2066300 See Plans and Pricing
Spain 2543349 See Plans and Pricing
Hong Kong 1126419 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Harvard Business School
Dow
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.